Furthermore, a Danish cohort study reported that cardioprotective glucose-lowering drugs, such as sodium–glucose cotransporter 2 inhibitors (SGLT-2I) or GLP-1 receptor agonists (GLP-1RA), are prescribed less often for women with type 2 diabetes and CVD [72]. Here, GLP1R is linked to type 2 diabetes mellitus.